Referring Clinicians
Thank you for your interest to consider your patients for early phase clinical trial enrollment. Here at the Auckland Cancer Trials Centre, we welcome referrals from across the whole of New Zealand.
This page contains the following information:
- An updated list of trials currently enrolling at our unit.
- Links to patient information summaries and key inclusion/exclusion criteria for each individual trial (feature in development)
- Instructions on how to refer your patients
Trials Recruiting at ACTC
| Tumour Stream | Trial Name | Study Description | Key Investigational Agent | Key Inclusion Criteria | Recruitment Status |
|---|---|---|---|---|---|
| Urothelial (Metastatic) | BGB-900-101 | Phase 2B study evaluating safety, tolerability, pharmacokinetics, and preliminary anti-tumour activity of Anti-PD-L1 antibody BGB-A333 in combination with Anti-PD-1 monoclonal antibody Tislelizumab in patients wth advanced urothelial carcinoma | BGB-A333(Anti PD-L1) +Tislelizumab(Anti PD-1) | Metastatic urothelial carcinoma after progression on platinum chemotherapy OR platinum intolerant | Recruiting |
| Multiple tumour stream : Squamous Cell Carcinoma: Head and Neck, (Metastatic), Upper Gastrointestinal (Oesophageal), Gynaecological (Cervical) | BP40234-FAP | Phase 2 study to evaluate the therapeutic activity of RO6874281 in combination with Atezolizumab in patients with advanced and/or metastatic solid tumors | Atezolizumab (Anti PDL1) + IL2variant | HNSCC • Checkpoint inhibitor naïve (≥ 1st line) • Checkpoint inhibitor exposed (≥ 2nd line) Cervix SCC • ≥ 2nd line Esophageal SCC • ≥ 2nd line | Recruiting |
| Upper Gastrointestinal (Advance) , Colorectal (Advance) | CITRON | Reducing Oxaliplatin Neurotoxicity: A Phase IB Randomized, Double-Blind, Placebo-Controlled, Crossover, Dose-Finding and Proof-of-Concept Trial of Cimetidine in Gastrointestinal Cancer Patients | mFOLFOX OR CAPOX +/- cimetidine | First 2 cycles mFOLFOX + cimetidine or placebo assessing for acute neuropathy. | Recruiting |
| Colorectal (Metastatic) | Medimmune | A phase 1/2 study of Durvalumab and Monalizumab in Adult Subjects with Select Advance Solid Tumours | Durvalumab (antiPDL1) [D] + Monalizumab (anti CD94/NKG2A) [M] + Cetuximab (EGFR inhibitor) [C] | Cohort A2 • First line, Microsatelite Stable, RAS/BRAF wildtype, left sided • All receive D+M+C+ mFOLFOX Cohort C : Any RAS, BRAF wildtype, microsatelite stable, must have been exposed to 5FU/Oxali/Irinotecan/Bevacizumab. 4 arms: • RAS mutant (D+M+C) • RAS wildtype (D+M+C) • RAS mutant (M+C) • RAS wildtype (M+C) | Recruiting |
| Merkel Cell | MK-3475-913 | A phase 1 open label, multi-arm , multicenter study of MK-1308 in combination with pembrolizumab for subjects with advanced solid organ tumours | Pembrolizumab(antiPD1) | • Unresectable Stage III and Stage IV Merkel Cell Carcinoma • 1st line | Recruiting |
| Prostate (mCRPC) | MK-3475-365 | Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365) | Pembrolizumab +Olaparib or Pembrolizumab +Abiraterone | Cohort A: (Pembro + Olaparib)- Must have received docetaxel +/- second chemo agent, up to 2 generation hormonal manipulations allowed (e.g. abiraterone, enzalutamide) Cohort D (Pembro + Abiraterone + Pred)- Chemo naïve for mCRPC (docetaxel allowed in mCNPC setting), no prior 2ng generation hormonal manipulation OR progressed on enzalutamide. | Recruiting |
How to Refer
Please email all referrals to CentralReferrals@adhb.govt.nz (include Att: ACTC in email subject)
Email us for any other inquiries: infoACTC@adhb.govt.nz
Auckland Cancer Trials Centre
Auckland City Hospital,
2, Park Road, Grafton,
1023, Auckland, New Zealand
Patient Referrals
Please email all referrals to: CentralReferrals@adhb.govt.nz (include Att: ACTC in email subject)